Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital
Everolimus is an effective treatment for advanced and/or metastatic breast cancer, especially in hormone receptor-positive cases. However, adverse events have prevented considerable numbers of clinicians from using this drug. Herein, we reviewed our clinical experiences and endeavored to identify pa...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2018-07-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/490787 |
| _version_ | 1819204119144955904 |
|---|---|
| author | Yuko Yoshida-Ichikawa Masahiko Tanabe Emi Tokuda Hideo Shimizu Yoshiya Horimoto Kayo Miura Mitsue Saito |
| author_facet | Yuko Yoshida-Ichikawa Masahiko Tanabe Emi Tokuda Hideo Shimizu Yoshiya Horimoto Kayo Miura Mitsue Saito |
| author_sort | Yuko Yoshida-Ichikawa |
| collection | DOAJ |
| description | Everolimus is an effective treatment for advanced and/or metastatic breast cancer, especially in hormone receptor-positive cases. However, adverse events have prevented considerable numbers of clinicians from using this drug. Herein, we reviewed our clinical experiences and endeavored to identify patients in whom the benefits of everolimus treatment would outweigh these adverse events. If measures were available to prevent or minimize adverse effects prior to treatment, everolimus would be a more widely applicable drug. This retrospective study involved 11 patients in whom nonresectable or recurrent breast cancers were treated with everolimus between April 2014 and January 2016. Two patients achieved a partial response (PR) and 4 showed stable disease (SD) (1 showed long SD, i.e., > 24 weeks). The response rate was 18%, and the clinical benefit rate (PR + long SD) was 27%. Regarding adverse events, interstitial pneumonia (grade 3) developed in 3 patients (18%), necessitating treatment discontinuation. When using everolimus, it may be important to select suitable patients for whom this treatment can be continued with sufficient control of adverse events. Herein, we provide information relevant to the clinical use of everolimus based on our daily practice experiences with this agent. |
| first_indexed | 2024-12-23T04:30:44Z |
| format | Article |
| id | doaj.art-727af2d0930b40df94575cde3ed712a2 |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-23T04:30:44Z |
| publishDate | 2018-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-727af2d0930b40df94575cde3ed712a22022-12-21T18:00:03ZengKarger PublishersCase Reports in Oncology1662-65752018-07-0111251152010.1159/000490787490787Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our HospitalYuko Yoshida-IchikawaMasahiko TanabeEmi TokudaHideo ShimizuYoshiya HorimotoKayo MiuraMitsue SaitoEverolimus is an effective treatment for advanced and/or metastatic breast cancer, especially in hormone receptor-positive cases. However, adverse events have prevented considerable numbers of clinicians from using this drug. Herein, we reviewed our clinical experiences and endeavored to identify patients in whom the benefits of everolimus treatment would outweigh these adverse events. If measures were available to prevent or minimize adverse effects prior to treatment, everolimus would be a more widely applicable drug. This retrospective study involved 11 patients in whom nonresectable or recurrent breast cancers were treated with everolimus between April 2014 and January 2016. Two patients achieved a partial response (PR) and 4 showed stable disease (SD) (1 showed long SD, i.e., > 24 weeks). The response rate was 18%, and the clinical benefit rate (PR + long SD) was 27%. Regarding adverse events, interstitial pneumonia (grade 3) developed in 3 patients (18%), necessitating treatment discontinuation. When using everolimus, it may be important to select suitable patients for whom this treatment can be continued with sufficient control of adverse events. Herein, we provide information relevant to the clinical use of everolimus based on our daily practice experiences with this agent.https://www.karger.com/Article/FullText/490787Breast cancerEverolimusAdverse eventsEstrogen receptorPI3K/Akt/mTOR |
| spellingShingle | Yuko Yoshida-Ichikawa Masahiko Tanabe Emi Tokuda Hideo Shimizu Yoshiya Horimoto Kayo Miura Mitsue Saito Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital Case Reports in Oncology Breast cancer Everolimus Adverse events Estrogen receptor PI3K/Akt/mTOR |
| title | Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital |
| title_full | Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital |
| title_fullStr | Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital |
| title_full_unstemmed | Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital |
| title_short | Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital |
| title_sort | overcoming the adverse effects of everolimus to achieve maximum efficacy in the treatment of inoperable breast cancer a review of 11 cases at our hospital |
| topic | Breast cancer Everolimus Adverse events Estrogen receptor PI3K/Akt/mTOR |
| url | https://www.karger.com/Article/FullText/490787 |
| work_keys_str_mv | AT yukoyoshidaichikawa overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital AT masahikotanabe overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital AT emitokuda overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital AT hideoshimizu overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital AT yoshiyahorimoto overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital AT kayomiura overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital AT mitsuesaito overcomingtheadverseeffectsofeverolimustoachievemaximumefficacyinthetreatmentofinoperablebreastcancerareviewof11casesatourhospital |